Stifel Nicolaus lowered shares of Hikma Pharmaceuticals Plc (LON:HIK) to a hold rating in a research note released on Tuesday morning. They currently have GBX 1,320 ($17.07) target price on the stock, down from their prior target price of GBX 2,300 ($29.75).
A number of other equities analysts also recently issued reports on HIK. Goldman Sachs Group, Inc. (The) downgraded shares of Hikma Pharmaceuticals Plc to a neutral rating and dropped their price objective for the company from GBX 2,600 ($33.63) to GBX 1,310 ($16.94) in a research note on Tuesday, August 22nd. Citigroup Inc. reiterated a neutral rating and set a GBX 1,350 ($17.46) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 24th. Barclays PLC dropped their price objective on shares of Hikma Pharmaceuticals Plc from GBX 2,200 ($28.45) to GBX 1,500 ($19.40) and set an overweight rating on the stock in a research note on Friday, August 25th. Numis Securities Ltd reiterated an add rating and set a GBX 1,560 ($20.18) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Friday, August 11th. Finally, Morgan Stanley downgraded shares of Hikma Pharmaceuticals Plc to an equal weight rating and dropped their price objective for the company from GBX 1,600 ($20.69) to GBX 1,350 ($17.46) in a research note on Monday, August 21st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of GBX 1,574.18 ($20.36).
Shares of Hikma Pharmaceuticals Plc (LON HIK) opened at 1231.00 on Tuesday. The stock has a 50 day moving average price of GBX 1,345.28 and a 200-day moving average price of GBX 1,733.12. The company’s market capitalization is GBX 2.95 billion. Hikma Pharmaceuticals Plc has a 12 month low of GBX 1,101.00 and a 12 month high of GBX 2,346.00.
COPYRIGHT VIOLATION WARNING: This story was first reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://transcriptdaily.com/2017/09/01/hikma-pharmaceuticals-plc-hik-cut-to-hold-at-stifel-nicolaus.html.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.